# Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

> **NCT00413322** · PHASE1 · COMPLETED · sponsor: **Valerio Therapeutics** · enrollment: 35 (actual)

## Conditions studied

- Tumor

## Interventions

- **DRUG:** belinostat
- **DRUG:** 5-Fluorouracil (5-FU)

## Key facts

- **NCT ID:** NCT00413322
- **Lead sponsor:** Valerio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-03
- **Final completion:** 2008-06
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2015-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00413322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00413322, "Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00413322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*